Alterations of fibrinolytic activity in human during and after hyperbaric oxygen exposure. 1996

N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
2nd Department of Physiology, Miyazaki Medical College.

To clarify the stage of fibrinolytic activation by hyperbaric oxygen (HBO) exposure, we examined its alterations in human during and after the HBO exposure. Eight healthy female volunteers breathed oxygen at 284 kPa (2.8 atmospheres absolute). Blood samples were collected before compression, shortly after compression to the pressure 284 kPa, shortly before the start of decompression, shortly after decompression, and then again 3 hours after decompression. We estimated the euglobulin fibrinolytic activity (EFA) and, the activities and antigens of both tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). The PAI-1 activity and PAI-1 antigen showed significant decrease after compression to a pressure 284 kPa, before the start of decompression, and after decompression. The EFA level and t-PA activity rose significantly shortly after decompression, and 3 hours later returned on baseline. These findings suggest that fibrinolytic activity is elicited after HBO rather than during HBO.

UI MeSH Term Description Entries
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006931 Hyperbaric Oxygenation The therapeutic intermittent administration of oxygen in a chamber at greater than sea-level atmospheric pressures (three atmospheres). It is considered effective treatment for air and gas embolisms, smoke inhalation, acute carbon monoxide poisoning, caisson disease, clostridial gangrene, etc. (From Segen, Dictionary of Modern Medicine, 1992). The list of treatment modalities includes stroke. Oxygenation, Hyperbaric,Hyperbaric Oxygen Therapy,Hyperbaric Oxygen Therapies,Hyperbaric Oxygenations,Oxygen Therapies, Hyperbaric,Oxygen Therapy, Hyperbaric,Oxygenations, Hyperbaric,Therapies, Hyperbaric Oxygen,Therapy, Hyperbaric Oxygen
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D012712 Serum Globulins All blood proteins except albumin ( Euglobulin,Euglobulins,Pseudoglobulin,Pseudoglobulins,Serum Globulin,Globulin, Serum,Globulins, Serum

Related Publications

N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
January 1995, Clinical and experimental pharmacology & physiology,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
October 2006, American journal of physiology. Heart and circulatory physiology,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
January 1972, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
October 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
June 1994, Aviation, space, and environmental medicine,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
October 1987, Canadian journal of physiology and pharmacology,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
February 1980, Journal of applied physiology: respiratory, environmental and exercise physiology,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
July 1999, Mutation research,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
May 1969, British heart journal,
N Yamami, and K Shimaya, and A M Sera, and H Fujita, and M Shibayama, and Y Mano, and M Maruyama, and H Mihara
December 2011, Acta ophthalmologica,
Copied contents to your clipboard!